Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246090 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 298
- Enrollment target
NCT00246090 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 298 participants.
The verdict
NCT00246090, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 298 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who are refractory to the last prior therapy for their disease.
Interventions
- DRUG E7389
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246090
The ClinicalTrials.gov registry entry for NCT00246090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E7389 is the first listed.
NCT00246090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246090 about?
NCT00246090 is a clinical study titled "A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine". The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who are refractory to the last prior therapy for their disease.
What is the current status of trial NCT00246090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2005-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00246090?
The interventions under investigation include: E7389 (DRUG).
Who is sponsoring clinical trial NCT00246090?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.